MoonLake director receives 22,195 share option grant

MoonLake Immunotherapeutics director Andrew John Phillips received a grant of stock options covering 22,195 shares.

Rhea-AI Filing Summary

MoonLake Immunotherapeutics director Andrew John Phillips received a grant of stock options covering 22,195 shares. These options have an exercise price of $19.19 per share and relate to Class A ordinary shares.

The options vest in full on the earlier of June 17, 2027 or the date of MoonLake’s next annual general meeting of shareholders, as long as he continues serving the company. After this grant, the filing shows 22,195 options held directly.

Insider Trade Summary

Grant/Award: 22,195 shares

Grant/Award 1 txn

Insider Phillips Andrew John

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option to Buy	22,195	$0.00	$0.00

Holdings After Transaction: Option to Buy — 22,195 contracts (Direct)

Footnotes (1)

1. F1. This option represents a right to purchase a total of 22,195 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer.

Key Figures

Option grant size: 22,195 shares Exercise price: $19.19 per share Options after transaction: 22,195 options +2 more

5 metrics

Option grant size 22,195 shares Options to buy Class A ordinary shares granted to director

Exercise price $19.19 per share Conversion or exercise price of granted options

Options after transaction 22,195 options Total derivative securities following transaction

Option expiration date June 17, 2036 Expiration date of stock options

Vesting condition date June 17, 2027 Latest vesting date or earlier next annual general meeting

Key Terms

Option to Buy, Class A ordinary shares, exercise price, vest in full, +1 more

5 terms

Option to Buy financial

"security_title: Option to Buy"

Class A ordinary shares financial

"underlying_security_title: Class A ordinary shares, par value $0.0001 per share"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

exercise price financial

"conversion_or_exercise_price: 19.1900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in full financial

"which will vest in full the earlier of (i) June 17, 2027"

annual general meeting of shareholders financial

"the date of the Issuer's next annual general meeting of shareholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MoonLake Immunotherapeutics (MLTX) report on this Form 4?

MoonLake Immunotherapeutics reported a director receiving a stock option grant for 22,195 shares. The options were granted as compensation, not purchased in the open market, and give the right to buy Class A ordinary shares at a fixed exercise price.

How many MoonLake Immunotherapeutics (MLTX) shares are covered by the new option grant?

The new option grant covers 22,195 Class A ordinary shares of MoonLake Immunotherapeutics. This entire amount is reflected as the director’s option holdings following the transaction, according to the Form 4 insider filing data provided.

What is the exercise price of the MoonLake Immunotherapeutics (MLTX) options granted?

The options were granted with an exercise price of $19.19 per share. This means the director can buy MoonLake’s Class A ordinary shares at $19.19 once the options have vested, regardless of the market price at that time.

When do the new MoonLake Immunotherapeutics (MLTX) options vest?

The options vest in full on the earlier of June 17, 2027, or the date of MoonLake’s next annual general meeting. Vesting is conditional on the director’s continued service to MoonLake Immunotherapeutics through that vesting date, as described in the footnote.

Are the MoonLake Immunotherapeutics (MLTX) options held directly or indirectly by the director?

The Form 4 shows the options as directly owned by the reporting person. The ownership code is listed as direct, and there is no footnote indicating that the options are held through an entity, trust, or other indirect structure.

Did the MoonLake Immunotherapeutics (MLTX) director buy or sell shares in the market in this filing?

The filing reports only a grant of options, not open-market buying or selling. The transaction code is “A,” indicating a grant or award acquisition, and there are no reported purchases or sales of common shares in this Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 06:45 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Phillips Andrew John

(Last) (First) (Middle)

C/O MOONLAKE IMMUNOTHERAPEUTICS

DORFSTRASSE 29

(Street)

ZUG 6300

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
MoonLake Immunotherapeutics [ MLTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Buy	$19.19	06/17/2026		A		22,195		(1)	06/17/2036	Class A ordinary shares, par value $0.0001 per share	22,195	$0.00	22,195	D

Explanation of Responses:

1. This option represents a right to purchase a total of 22,195 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer.

	/s/ Matthias Bodenstedt, Attorney-in-fact for Andrew John Phillips	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)